Sugi Predict

Sugi Predict / Compounds / SCHEMBL626017

SCHEMBL626017

SCHEMBL626017

COC(=O)[C@@H]1CC[C@H](C)N1C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ TSHR P16473 1/20 0.38
▸ PREP P48147 4/20 0.38
▸ PTPN1 P18031 1/20 0.37
▸ EPHX1 P07099 1/20 0.36
▸ NR1H2 P55055 1/20 0.35
▸ NR1H3 Q13133 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ FKBP1A P62942 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ELANE P08246 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5964813 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3TSHRPREP
SCHEMBL883196 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3TSHRPREP
SCHEMBL27379896 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3TSHRPREP
SCHEMBL476260 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3TSHRPREP
SCHEMBL476259 1.00 CHRM2 (0.45) CHRM2CHRM1CHRM3TSHRPREP
SCHEMBL18018299 0.91 CHRM2 (0.43) CHRM2CHRM1CHRM3TSHRPREP
SCHEMBL21441862 0.91 CHRM2 (0.43) CHRM2CHRM1CHRM3TSHRPREP
SCHEMBL19654088 0.90 CHRM2 (0.47) CHRM2CHRM1CHRM3PREPEPHX1
SCHEMBL17040995 0.90 CHRM2 (0.50) CHRM2CHRM1CHRM3PREPPTPN1
SCHEMBL22086379 0.90 CHRM2 (0.50) CHRM2CHRM1CHRM3PREPPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 — — US disclosed
US-11718638-B2 Compounds, compositions and methods for synthesis WAVE LIFE SCIENCES LTD. (SG) 2023-08-08 — — US disclosed
WO-2019164778-A1 PROCESS FOR PREPARING 1-ARYLSULFONYL-PYRROLIDINE-2-CARBOXAMIDE TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST COMPOUNDS AND CRYSTALLINE FORMS THEREOF GENENTECH, INC. (US) 2019-08-29 — — WO disclosed
EP-3514158-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Aptinyx Inc. (US) 2019-07-24 — — EP disclosed
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
US-9579304-B2 Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx, Inc. (US) 2017-02-28 — — US disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 — — US disclosed
EP-2414350-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-11-12 — — EP disclosed
US-8796466-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-05 — — US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 — — EP disclosed
WO-2013095275-A1 NOVEL HEPATITIS C VIRUS INHIBITORS MEDIVIR AB (SE) 2013-06-27 — — WO disclosed
EP-2603504-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2013-06-19 — — EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 — — US disclosed
US-20120195857-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-08-02 — — US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 — — WO disclosed
WO-2012039717-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-29 — — WO disclosed
WO-2012021591-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-16 — — WO disclosed
US-20110237636-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-09-29 — — US disclosed
US-20110237636-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-09-29 — — US disclosed
WO-2010117635-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237636-A1 Hepatitis C Virus Inhibitors HAVCR2, EIF2AK2, MAVS CHRM2 4839/4885CHRM1 4819/4885CHRM3 4737/4885
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL CHRM2 1629/4885CHRM1 684/4885CHRM3 2542/4885
US-11718638-B2 Compounds, compositions and methods for synthesis ALKBH1, DUT, RNGTT CHRM2 4024/4885CHRM1 3580/4885CHRM3 3179/4885
US-20120195857-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 CHRM2 945/4885CHRM1 1134/4885CHRM3 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.